24Business
IMCAS 2025: The new Galderma Phase IIIB data enhances a quick start and a long aesthetic improvement with Relabotulinumtoxin (RelfyDess ™)
IMCAS 2025: The new Galderma Phase IIIB data enhances a quick start and a long aesthetic improvement with Relabotulinumtoxin (RelfyDess ™)
Source link